Spondyloarthritis & psoriatic arthritis
Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden
Authors' conclusion
From 2014 to 2016, the annual incidence of clinically diagnosed PsA in the adult Swedish population was approximately 20 per 100,000 PYs at risk. Two years after diagnosis, almost three-quarters of patients had received DMARD therapy.
Study context
- Population
- Adults (≥18 years) with incident clinically diagnosed psoriatic arthritis (PsA) in Sweden, identified from the National Patient Register and/or the Swedish Rheumatology Quality Register
- Outcome
- Mean annual incidence of clinically diagnosed PsA (base case definition)
- Follow-up
- 2014-2016
Methodological detailsnationwide, register-based
- Nationwide
- Register-based
Main finding
As reported in the abstract
Base case definition
21.77 per 100,000 person-years (PYs) at risk
After accounting for diagnostic misclassification
17.41 per 100,000 PYs at risk
Range across all sensitivity analyses
15.78 to 28.83 per 100,000 PYs at risk
Observational data: associations, not effects.
Further findings
Incidence by sex, education and age
- Slightly higher in female individuals, lower in those with higher education (>12 years), peaked at ages 50 to 59 years
Time trend in incidence · 2006-2018
- No apparent increasing or decreasing time trend
DMARD therapy received within 2 years of diagnosis
- Any DMARD
- 71.03%
- b/tsDMARD
- 22.37%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →